Original Research ArticleInternational Journal of Basic & Clinical Pharmacology
Publication: Comparative study to evaluate efficacy and safety of azilsartan and telmisartan in patients with grade I-II essential hypertension
Int J Basic Clin Pharmacol. 2018;7(1):184-190.DOI10.18203/2319-2003.ijbcp20175697
Abstract
Background Objectives of the study was to study the effect of Azilsartan 40mg once daily versus Telmisartan 40mg once daily in patients with Grade I-II essential hypertension.
Methods A prospective study was conducted at MGM Medical college and Hospital which included 80 patients in each group with Grade I–II essential hypertension. The sex, age, presenting illness, and family history of the patients were recorded. Investigations such as blood sugar, urine analysis, kidney function test, lipid profile, and ECG were performed before starting the treatment. Any adverse effects during the treatment were noted. Blood pressure was recorded at baseline and during follow-up. One group received Azilsartan 40mg once daily and another group Telmisartan 40mg once daily. Patients were followed-up every week for 5 weeks.
Results Patients receiving Azilsartan 40mg and Telmisartan 40mg showed a significant fall (P 0.05). Adverse effects such as Nasopharyngitis, Upper respiratory tract inflammation, Gastroenteritis, headache, dizziness, and fatigue were reported with both drugs.
Conclusions Reduction of blood pressure with Azilsartan and Telmisartan was similar, but fall in blood pressure from baseline was highly significant in both groups.
Keywords
Affiliations
- Department of Pharmacology, MGM Medical College and Hospital, Aurangabad, Maharashtra, India
